Skip to content

Michael Evans‐brown

2 papers in the library · 193 citations · publishing 2014-2021

Papers

The new drug phenomenon

Drug Testing and Analysis July 1, 2014 Simon D. Brandt, Leslie A. King, Michael Evans‐brown 164 citations

The new drug phenomenon over the past decade has been driven by the commodification of a wide range of psychoactive substances not controlled under drug laws, sold openly as 'legal highs', 'bath salts', or 'research chemicals' by entrepreneurs and criminal groups, especially via the Internet. In Europe, the rate of appearance of new psychoactive substances (NPS) averaged one new substance every 5–6 days, with 81 detected in 2013, 74 in 2012, 49 in 2011, and 41 in 2010. The number of Internet shops selling these substances rose from 170 in 2010 to 693 in 2012 and 651 in 2013. Many substances were originally synthesized years ago, some as failed pharmaceuticals, and their re-discovery has fueled the market.

Eutylone and Its Structural Isomers Interact with Monoamine Transporters and Induce Locomotor Stimulation

ACS Chemical Neuroscience March 9, 2021 Grant C. Glatfelter, Donna Walther, Michael Evans‐brown et al. 29 citations

Eutylone, a new synthetic cathinone appearing in recreational drug markets, acts as a hybrid monoamine transporter compound. In rat brain tissue, eutylone inhibited dopamine and norepinephrine uptake (most potently at dopamine transporters, IC50 = 120 nM) and showed weak partial serotonin-releasing activity. It stimulated locomotion in mice (ED50 = 2 mg/kg), indicating psychostimulant effects similar to pentylone, suggesting abuse liability and risk of adverse effects in humans.